Earnings: Tough Times Ahead

Gopal,Kevin;

Article

Pharmaceutical Executive

March 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-03-01-2001

Volume0

Issue 0

Earnings: Tough Times Ahead

Author(s):

Kevin Gopal

Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.

Articles in this issue

Research: New Horizons

Earnings: Tough Times Ahead

Outbreak: Anthrax Alarm

Patents: China on the Genome Map

Privacy, Pediatrics, and Policy

Lilly's International Family

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Earnings: Tough Times Ahead

Newsletter